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Abstract
Background: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder with an estimated prevalence of
4–21% in reproductive aged women. The altered metabolic and hormonal environment among women with PCOS
may increase their risk of some types of cancer.
Methods: We performed a comprehensive review of the literature using numerous search terms for all studies
examining the associations between polycystic ovary syndrome and related characteristics and cancer published
in English through October 2016. This review summarizes the epidemiological findings on the associations
between PCOS and endometrial, ovarian, and breast cancers and discusses the methodological issues, complexities,
and underlying mechanisms of these associations.
Results: We identified 11 individual studies and 3 meta-analyses on the associations between PCOS and endometrial
cancer, 8 studies and 1 meta-analysis for ovarian cancer, and 10 studies and 1 meta-analysis for breast cancer. Multiple
studies reported that women with PCOS were at a higher risk for endometrial cancer; however, many did not take into
account body mass index (BMI), a strong and well-established risk factor for endometrial cancer. The association with
ovarian cancer was less clear, but a potentially increased risk of the borderline serous subtype was reported by two
studies. No consistent association between PCOS risk and breast cancer was observed.
Conclusion: The associations between PCOS and endometrial, ovarian, and breast cancer are complex, with the need
to consider many methodological issues in future analyses. Larger well-designed studies, or pooled analyses, may help
clarify these complex associations.
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Background
Polycystic ovary syndrome (PCOS) is a complex endo-
crine disorder characterized by oligomenorrhea, hyper-
androgenism, and polycystic ovaries. It has an estimated
prevalence of 4–21% in reproductive aged women de-
pending on the diagnostic criteria and population exam-
ined [1–7]. In the U.S. it has been estimated that 5
million women may have PCOS [8]. PCOS is associated
with metabolic abnormalities including dyslipidemia,
insulin resistance, and type II diabetes and is also one of
the most common causes of reduced fertility [9, 10]. The
altered metabolic and hormonal environment among
women with PCOS may increase their risk of some types
of cancer.
First described by Stein and Leventhal in 1935 as
women with polycystic ovaries, amenorrhea, and hir-
sutism [11], PCOS is currently clinically identified by
one of three diagnostic criteria set by the National
Institutes of Health/National Institute of Child Health
and Human Disease (NIH/NICHD),[12] European
Society for Human Reproduction and Embryology/
American Society for Reproductive Medicine (ESHRE/
ASRM) (Rotterdam criteria),[13] and Androgen Excess
and PCOS Society [14]. While the definitions are
* Correspondence: hharris@fredhutch.org
1Program in Epidemiology, Division of Public Health Sciences, Fred
Hutchinson Cancer Research Center, M4-859 Seattle, WA, USA
2Department of Obstetrics and Gynecology, Brigham and Women’s Hospital
and Harvard Medical School, Boston, MA, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Harris and Terry Fertility Research and Practice  (2016) 2:14 
DOI 10.1186/s40738-016-0029-2
similar with regard to assessment of menstrual history
and androgen excess (defined by clinical characteris-
tics or serum androgen levels) they differ in that the
NIH definition does not consider ovarian morphology
(Table 1). Thus, the prevalence of PCOS varies
depending on the diagnostic criteria used with the
NIH/NICHD criteria resulting in the lowest preva-
lence estimates followed by the Androgen Excess
Society and ESHRE/ASRM [3].
The clinical presentation of PCOS varies but com-
monly includes ovulatory dysfunction (oligomenorrhea,
irregular periods and/or anovulatory cycles), hirsutism,
acne, and polycystic ovaries (PCO). Women with PCOS
commonly have insulin resistance and metabolic syn-
drome [15–19]. In addition, they are also at increased
risk of type II diabetes,[20, 21] high cholesterol,[22–25],
high blood pressure,[26–28] and are more likely to be
overweight or obese [29–31]. Pharmacological agents are
the first- and second-line treatments for many PCOS
symptoms including: oral contraceptive use for oligo-
menorrhea, hirsutism, and acne; metformin for anovula-
tory infertility, oligomenorrhea, and type II diabetes
prevention and treatment; and ovulation induction drugs




An association between PCOS and endometrial cancer
was first suggested over fifty years ago by a series of
small case reports, but these studies were limited by lack
of control groups and small numbers [33]. Three meta-
analyses, with overlapping studies, have reported a sig-
nificant increased risk of endometrial cancer among
women with PCOS (Table 2) [34–36]. However, they
each included estimates from analyses that did not take
into account BMI which is a common characteristic of
PCOS and a strong and well-established risk factor for
endometrial cancer [37, 38].
Five studies have examined the association between
PCOS and endometrial cancer without accounting for
BMI (Table 2). Two of these were registry-based cohorts
reporting estimates of 3.9 (95% confidence interval [95%
CI] = 2.2–6.3) [39] and 4.7 (95% CI = 1.6–14.1). Three
case–control studies reported odds ratios (ORs) of 5.4
(95% CI = 2.4–12.3),[40] 8.9 (95% CI = 0.43–184.86),[41]
and 9.0 (95% CI = 0.5–176.1) [42]. In addition, two
studies examining chronic anovulation syndrome and
androgen excess/menstrual disorders as proxies for
PCOS, reported ORs of 3.1 (95% CI = 1.1–7.3) [43] and
2.0 (95% CI = 1.1–3.3),[44] respectively, while a study
examining polycystic ovarian morphology reported no
association (OR = 1.0; 95% CI = 0.4–2.7) [45]. Besides
lack of adjustment for BMI these studies were addition-
ally limited by a small number of exposed cases, consist-
ing of 16 or fewer cases with PCOS. In studies that have
reported effect estimates adjusted for BMI the observed
associations with PCOS and endometrial cancer have
been less consistent [46–48]. Wild et al. followed a co-
hort of women diagnosed with PCOS and reported an
increased risk of endometrial cancer in these women
compared to age-matched controls with OR of 5.3 (95%
CI = 1.5–18.6) without adjustment for BMI and 6.1 (95%
CI = 1.0–36.9) after adjustment for BMI [47]. In contrast,
Fearnley et al. reported an attenuation of the OR follow-
ing adjustment for BMI (OR = 4.0; 95% CI = 1.7–9.3 and
OR = 2.2; 95% CI = 0.9–5.7, respectively) [46]. Finally,
Zucchetto et al. observed no association between PCOS
and endometrial cancer with a BMI-adjusted OR of 1.3
(95% CI = 0.7–2.2) with an OR that was slightly higher
when limited to premenopausal women (OR = 2.0; 95%
CI = 0.8–5.4) (Table 2) [48]. Differences in these studies
may be due to varying control for confounders, Wild et
al. did not adjust for any variables except BMI while
Fearnley et al. adjusted for parity and oral contraceptive
(OC) use, and Zucchetto et al. adjusted for parity, OC
use, age at menarche, and age at menopause. In addition,
the study population in Fearnley, et al. was limited to
women under age 50 which is likely a primarily premen-
opausal population.
Endometrial tumors display a variety of histologic
features but the majority of cases are adenocarcin-
omas (>95%) and can be classified into two main sub-
types, endometrioid (Type I) and non-endometrioid
(Type II) [49, 50]. As approximately 70–80% of endo-
metrial cancers are Type I tumors the reported asso-
ciations between PCOS and endometrial cancer are
likely driven by this subtype. To our knowledge only
one study has examined the association between
PCOS and subtype specific endometrial cancer report-
ing a slightly stronger association between PCOS and
endometrial cancer when limited to Type I (OR all
cases = 2.2; 95% CI 0.9–5.7 vs. OR Type I cases = 2.4;
95% CI = 1.0–6.2) [46].
Table 1 Diagnostic criteria for PCOS
NIH 1990 Criteria Rotterdam Criteria AE-PCOS Society Criteria
Hyperandrogenism Required 2 out of 3 required Required
Ovulatory dysfunction (oligo- or amenorrhea) Required 2 out of 3 required Either ovulatory dysfunction or PCOS morphology required
PCOS morphology Not required 2 out of 3 required Either ovulatory dysfunction or PCOS morphology required
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Ovarian cancer
PCOS has been hypothesized to increase ovarian cancer
risk through increased androgen exposure [51]. Evidence
linking androgens to ovarian cancer includes the pres-
ence of androgen receptors on normal ovarian cells as
well as benign and borderline tumors, and a doubling of
androgen levels during pregnancy is associated with a
40–50% increased risk of borderline serous and invasive
mucinous tumors [51–53]. However, studies of prediag-
nostic androgen levels not during pregnancy have been
mixed [54–57]. With respect to PCOS specifically, nine
studies have examined the association with ovarian
cancer risk to date [39, 43, 44, 58–63]. Many of these
studies had limited power, with four studies having 12 or
fewer ovarian cancer cases (Table 3) [39, 43, 44, 60, 62].
Overall, studies of PCOS and ovarian cancer have been
largely null with some suggestion of an increased risk as
demonstrated by a recent meta-analysis of three studies
(OR = 1.4; 95% CI = 0.9–2.2) [34]. Since then a Danish
registry study reported a non-significant increase in
ovarian cancer risk for women with PCOS compared to
the general Danish female population (standardized inci-
dence ratio [SIR] = 1.8; 95% CI = 0.8–3.2), but the study
was limited by small numbers with only 10 ovarian cases
Table 2 Studies of PCOS and endometrial cancer risk
Author Year Study design Endometrial Cancer Cases (n) Overall result RR (95% CI)
Gottschau 2015 Registry cohort (Denmark) 16 3.9 (2.2–6.3)a
Shen 2015 Registry cohort (Taiwan) 7 4.7 (1.6–14.1)a
Barryb 2014 Meta-analysis 1264 2.8 (1.3–6.0)a
Haoulac 2012 Meta-analysis 938 2.9 (1.5–5.5)a
Brintond 2010 Cohort (US) 15 2.0 (1.1–3.3)a
Fearnleye 2010 Case control (Australia) 156 2.2 (0.9–5.7)
Chittendenf 2009 Meta-analysis 667 2.7 (1.0–7.3)c
Zucchetto 2009 Case–control (Italy) 454 1.3 (0.7–2.2)
Iatrakise 2006 Case–control (Greece) 81 9.0 (0.5–176.0)a,g
Pillayh 2006 Cross-sectional (UK) 128 1.0 (0.4–2.7)a,c
Niwa 2000 Case–control (Japan) 136 8.9 (0.4–184.9)a,g
Wild 2000 Cohort (UK) 11 6.1 (1.0–36.9)
Escobedo 1991 Case–control (US) 437 5.4 (2.4–12.3)a
Coulami 1983 Cohort (US) 5 3.1 (1.1–7.3)a
a Effect estimate not adjusted for BMI
b This meta-analysis includes the studies by Fearnley, Zucchetto, Iatrakis, Niwa, and Escobedo
c This meta-analysis includes the studies by Fearnley, Iatrakis, Pillay, Niwa, and Escobedo
d In this study, androgen excess or menstrual disorders was evaluated rather than PCOS
e This study only included women less than 50 years old
f This meta-analysis includes the studies by Iatrakis, Pillay, Niwa, and Escobedo
g Odds ratio was calculated based on numbers provided in the paper
h In this study, polycystic ovary morphology was evaluated rather than PCOS
i In this study, chronic anovulation syndrome was evaluated rather than PCOS
Table 3 Studies of PCOS and ovarian cancer risk
Author Year Study design Ovarian Cancer Cases (n) Overall result RR (95% CI)
Harris 2016 Case–control (US) 1513 1.0 (0.60–1.5)
Gottschau 2015 Registry Cohort (Danish) 10 1.8 (0.8–3.2)a
Shen 2015 Registry Cohort (Taiwan) 11 1.0 (0.2–4.6)a
Barryb 2014 Meta-analysis 3363 1.4 (0.9–2.2)a
Bodmer 2011 Case–control (UK) 1611 1.6 (0.7–4.1)a
Brintonc 2010 Cohort (US) 12 1.8 (0.9–3.1)a
Olsen 2008 Case–control (Australia) 1276 1.1 (0.6–2.0)
Schildkraut 1996 Case–control (US) 476 2.4 (1.0–5.9)a
Rossing 1994 Cohort (US) 11 2.4 (0.2–22.5)
a Effect estimate not adjusted for BMI
b This meta-analysis includes the studies by Bodmer, Olsen, and Schildkraut
c In this study, androgen excess or menstrual disorders was evaluated rather than PCOS
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[39]. In a recent Taiwanese study with only 11 ovarian
cancer cases, no association between PCOS and ovarian
cancer was observed (hazard ratio [HR] = 1.0; 95% CI =
0.2–4.6) [62]. In the New England Case–control (NECC)
study, which includes 1,513 ovarian cancer cases, we ob-
served no association between self-reported PCOS and
ovarian cancer risk (OR = 1.0; 95% CI = 0.6–1.5) [63].
Epithelial ovarian cancer consists of molecularly and
etiologically distinct subgroups that can be separated
into four main histologic subtypes [64–67]. Thus, an ele-
vation in risk relevant to only certain subtypes of ovarian
cancer could be missed if subgroup specific estimates of
ovarian cancer are not calculated. Only two studies to
date have examined the association by histologic sub-
type. Olsen, et al. reported an association between PCOS
and the borderline serous subtype (OR = 2.5; 95% CI
1.0–6.1) and noted this association was strongest among
women with a BMI ≥ 25 (OR = 3.0; 95% CI 1.2–7.5) [59].
Consistent with this result, we observed in the NECC
study of ovarian cancer the suggestion of an increased
risk of the borderline serous subtype for women with
PCOS (OR = 1.2; 95% CI 0.5–2.8) that was also stronger
among overweight women [63]. Serous borderline ovar-
ian tumors have been proposed to arise from benign
ovarian tumors [68] and have higher androgen receptor
levels than serous invasive tumors [52]. Furthermore, in a
large European prospective cohort study, prediagnostic
androstenedione was shown to increase risk of low-grade
tumors (OR = 1.99; 95% CI = 0.98–4.06) but decrease risk
of high grade tumors (OR = 0.75; 95% CI = 0.61–0.93)
[57]. Larger studies are needed to further examine
whether PCOS is associated with serous borderline
tumors and whether this association only pertains to over-
weight women.
Breast cancer
Characteristics and consequences of PCOS have been
previously associated with both increased and de-
creased risk of breast cancer. For example, infertility
due to an ovulatory disorder has been shown to de-
crease breast cancer risk [69] while obesity increases
breast cancer risk among postmenopausal women and
decreases risk among premenopausal women [38].
However, studies to date have not observed an associ-
ation between PCOS and breast cancer risk (Table 4).
A meta-analysis including two case–control studies
(from Italy and Iran) and one cohort study (Iowa
Women’s Health Study) reported no elevation in risk
for women with PCOS (OR = 1.0; 95% CI = 0.6–1.4)
[34]. Similarly, a recent Danish registry study showed
no association between PCOS and breast cancer risk
with 59 breast cases observed and 56 expected result-
ing in a standardized incidence ratio of 1.1 (95% CI =
0.8–1.4) [39] and a retrospective cohort study in
Taiwan showed no association (HR = 1.6, 95% CI =
0.9–2.8) [62].
Though women were not specifically classified by
PCOS status, we reported in the Nurses’ Health Study
II, a cohort including more than 100,000 women and
followed prospectively, that women who reported infer-
tility due to ovulatory disorders had no increase in
breast cancer risk. In fact, women with ovulatory disor-
ders that were treated for infertility had a significantly
lower risk compared to women with no reported infertil-
ity [69]. Anovulatory cycles skip the luteal phase of the
menstrual cycle and it is during the luteal phase that
estrogen and progesterone levels are both elevated [70].
In addition, breast cancer cell proliferation is higher dur-
ing the luteal phase [71, 72] thus women with ovulatory
Table 4 Studies of PCOS and breast cancer risk
Author Year Study design Breast Cancer Cases (n) Overall result RR (95% CI)
Gottschau 2015 Registry Cohort (Danish) 59 1.1 (0.8–1.4)a
Shen 2015 Registry Cohort (Taiwan) 44 1.6 (0.9–2.8)a
Barryb 2014 Meta-analysis 3618 1.0 (0.6–1.4)a
Ghasemi 2010 Case–control (Iran) 166 0.7 (0.3–1.5)a
Brintonc 2010 Cohort (US) 89 1.3 (1.1–1.6)a
Terryd 2006 Cohort (US) 2267 0.8 (0.6–1.0)
Wild 2000 Cohort (UK) 49 1.3 (0.6–2.8)
Anderson 1997 Cohort (US) 883 1.2 (0.7–2)
Talamini 1997 Case–control (Italy) 2569 0.9 (0.4–1.8)
Gammon 1991 Case–control (US) 4730 0.47 (0.3–0.9)a
Coulame 1983 Cohort (US) 12 1.5 (0.8–2.6)
a Effect estimate not adjusted for BMI
b This meta-analysis includes the studies by Ghasemi, Anderson, and Talamini
c In this study, androgen excess or menstrual disorders was evaluated rather than PCOS
d In this study, infertility due to ovulatory disorders was evaluated rather than PCOS
e In this study, chronic anovulation syndrome was evaluated rather than PCOS
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disorders will have a reduced lifetime exposure to luteal
phase hormones which may explain the observed reduc-
tion in risk.
Other cancers
The literature examining the association between PCOS
and cancers other than endometrial, breast, and ovarian,
is scarce. Although not previously described, more kid-
ney, colon, and brain cancers were observed among
women with PCOS compared to expected rates in the
general Danish population [39]. In addition, Brinton et
al. reported a significant standardized incidence ratio for
melanoma (SIR = 2.0; 95% CI = 1.1–3.2) among infertile
women with androgen excess or menstrual cycle disor-
ders compared to the general U.S. population [44].
These findings need to be followed up in large well-
designed studies for validation.
Discussion
Confounding and mediation
Since high BMI is a common characteristic of PCOS,
[29–31] one cannot exclude the possibility that reported
associations may be attributable to a higher BMI in
women with PCOS, on average. As noted above, many
studies failed to control for BMI and when BMI is taken
into account residual confounding may remain since
weight is strongly associated with these diseases. In fact,
the inverse association between BMI and breast cancer
among premenopausal women but positive association
among postmenopausal women may explain, in part, the
lack of an association with breast cancer [38]. Con-
versely, there is evidence that PCOS influences body size
through dietary intake and cravings,[73, 74] as well as
through its influence on metabolic factors that may
impact weight gain [75–81]. Thus BMI may be both a
mediator and confounder of the PCOS and cancer asso-
ciations making it difficult to characterize a BMI-
independent PCOS association.
Beyond BMI, the adjustment for cancer risk factors
varied widely between studies and may also explain
differences between studies as some characteristics of
PCOS, such as infertility, are risk factors for these can-
cers. Reproductive risk factors such as parity and age at
first birth may have different distributions in those with
and without PCOS due to the increased risk of infertility
in women with PCOS. In addition, women with PCOS
are at increased risk of type II diabetes [20, 21], insulin
resistance, and metabolic syndrome [15–19]. These condi-
tions have been associated with cancer risk,[82, 83] and
thus could serve either as potential confounders or inter-
mediates, of the PCOS-cancer association. A few studies
have adjusted for these potential intermediate variables
(i.e. hypertension and diabetes), which may have resulted
in an attenuation of the true association [46, 62].
Possible biologic mechanisms
PCOS is characterized by prolonged anovulation with
consequent exposure to estrogen unopposed by proges-
terone [33, 84], which may explain why women with
PCOS have an elevated risk of endometrial cancer, an
estrogen-sensitive disease. The association between
estrogen and breast or ovarian cancer are more complex
and depend on subtypes of disease and menopausal sta-
tus,[65, 66, 85, 86] which may explain the lack of overall
increased risk for these cancers. Larger studies, or
pooled analyses, are needed which would allow investi-
gation of these associations by specific subtypes and
menopausal status.
Alternatively, elevated androgens may play a role.
Hyperandrogenism is one major component of all three
clinical diagnostic criteria for PCOS. In 1998, Risch pro-
posed that ovarian cancer might be associated with fac-
tors related to androgen stimulation of ovarian cells,[51]
and animal studies have demonstrated that testosterone
stimulates the growth of epithelial cells in the ovary [87].
The suggestion of an increased risk of the borderline
serous subtype of ovarian cancer among women with
PCOS supports the hypothesis that androgens could be
a factor in ovarian cancer development as androgen
receptors have been shown to be higher in serous
borderline tumors compared to serous invasive [52].
Circulating androgens may also play a role in breast
carcinogenesis [88]. In a pooled analysis of prospect-
ive studies, risk of breast cancer has been shown
increase with increasing testosterone levels in post-
menopausal women [89]. A similar increased risk has
been reported by cohort studies among premeno-
pausal women [90, 91].
PCOS medications that may influence cancer risk
Oral contraceptives
For women who are not attempting to become preg-
nant, combined oral contraceptives are often one of
the first-line treatments for menstrual irregularities in
women with PCOS [92]. Combined oral contracep-
tives are associated with decreased risk of ovarian
[93] and endometrial cancers [94]. The protective
effect of oral contraceptives on ovarian cancer risk is
likely explained by a decreased lifetime number of po-
tentially damaging ovulations,[95] while the protective
effect in endometrial cancer may be the result of re-
ducing exposure to unopposed estrogen which limits
the cell proliferation that is stimulated by estrogens
[84]. In contrast, oral contraceptives may result in a
very small short-term increase in breast cancer risk,
while 10 years after cessation of use the risk among
women who had used oral contraceptives was similar
to those who had not used oral contraceptives [96].
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Metformin
Among women with PCOS, metformin is prescribed to
treat or reduce the risk of type II diabetes, improve insu-
lin resistance, and in some cases to help regulate the
menstrual cycle/induce ovulation. Evidence has sug-
gested that metformin use may be protective against
various forms of cancer. This is supported by laboratory
studies that demonstrate metformin’s anti-cancer activ-
ities [97]. However, fewer studies have examined the
impact of metformin on incidence of endometrial,
breast, and ovarian cancer.
Breast cancer has been the most studied of the three
cancers with respect to the influence of metformin. A
2014 meta-analysis including 13 studies reported a sum-
mary risk estimate (SRR) of 0.9 (95% CI = 0.8–1.0) for
the association between metformin use and breast can-
cer incidence [98]. When limited to the studies which
adjusted for BMI (n = 7), an established risk factor for
postmenopausal breast cancer, the SRR was 0.8 (95%
CI = 0.7–1.0), and when limited to prospective studies
(n = 7), the SRR was 0.9 (95% CI = 0.9–1.0). However,
a more recent analyses among women in general
practice databases from Germany and the United
Kingdom reported no association between metformin
users and breast cancer incidence when compared users
of sulfonylurea and insulin (HR = 1.0; 95% CI = 0.8–1.3
and HR = 1.1; 95% CI = 0.7–1.7, respectively) [99].
The epidemiologic data examining the relation be-
tween metformin and endometrial cancer have generally
suggested no association or a protective association be-
tween metformin and endometrial cancer. Among
women in the UK-based General Practice Research
Database (GPRD) no significant association was ob-
served between metformin and endometrial cancer with
an OR of 0.9 (95% CI = 0.6–1.2) [100] Similarly, in a
retrospective cohort analysis of US healthcare claims
data no association was observed between metformin
use and endometrial cancer (HR = 1.1; 95% CI = 0.9–
1.4) [101]. Most recently, Tseng reported an inverse
association between metformin and endometrial
cancer among women with type II diabetes in the
National Health Insurance database in Taiwan (HR =
0.7; 95% CI = 0.6–0.7) [102].
The association between metformin use and ovarian
cancer has been less studied than breast or endometrial
cancer. However, metformin use has been demonstrated
to influence ovarian cancer cell growth in vitro and in
vivo [103, 104] and has been associated with survival in
patients with ovarian cancer [105, 106]. To our know-
ledge, only one observational study has reported the
association between metformin and risk of ovarian cancer
observing the suggestion of a decreased risk of ovarian
cancer with increasing metformin use (OR = 0.6; 95% CI =
0.3–1.3) among women in the UK-based GPRD [58].
Ovulation-induction therapies
Previous studies on the associations between fertility
drugs and risk of hormone related cancers have pro-
duced mixed results. The inconsistencies are likely due
to the combining of different drug types, self-reported
drugs use, limited power and information about dosages,
short follow-up, and reproductive confounders that are
highly correlated with drug use [107]. Clomiphene (clo-
mid), a common treatment for PCOS-associated infertil-
ity, is a selective estrogen receptor modulator that
stimulates the ovaries to ovulate but can increase or
decrease estrogen receptor activation in other tissues. In
breast cancer cell lines, clomiphene has a pro-apoptotic
effect,[108] which may explain why women who received
clomiphene for PCOS-related infertility have a reduced
breast cancer risk in some studies [69, 109]. A more
recent study in a cohort of over 12,000 infertile women
reported that clomiphene was not associated with breast
cancer risk, although a non-significant increased risk
was observed for those with over 12 cycles [110].
Clomiphene’s action as an ovulation inducer provides
strong biological plausibility for its influence on ovarian
cancer risk as ovulatory damage likely plays a prominent
role in ovarian cancer risk [95]. Most recent studies have
indicated no significant increased risk of ovarian cancer
among clomiphene users [107]. In a large cohort of
women evaluated for infertility with extended follow-up
Trabert, et al. reported no overall association between
clomiphene use and ovarian cancer risk (HR = 1.3; 95%
CI = 0.9–2.1), however they did note an increased risk
among women who remained infertile (HR = 3.6; 95%
1.4–9.7) [111] and this increased risk in nulligravid
women has been observed in other studies [107].
Whether this indicates confounding by infertility severity
or a true effect deserves further study.
Endometrial cancer has been the least studied of the
hormone related cancers in relation to clomiphene use.
An association has been hypothesized since clomiphene
has chemical properties similar to tamoxifen, a drug that
has been associated with endometrial cancer risk [112].
However, most previous studies of clomiphene and
endometrial cancer have been limited by power [107]. In
one of the largest studies to date Brinton et al. reported
a slight non-significant increase in risk of endometrial
cancer among clomiphene users (HR = 1.4; 95% CI =
1.0–2.0) [113].
Fewer studies have examined the associations between
clomiphene and cancers other then endometrial, ovarian,
or breast cancer. A recent analysis in a cohort of over
12,000 infertile women reported that clomiphene was
statistically significant increased risk of melanoma
(HR = 2.0; 95% CI = 1.2–3.2), a non-significant increased
risk of thyroid cancer (1.6; 95% CI = 0.9–2.8), and no
increased risks for colorectal or lung cancer [114].
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Letrozole, an aromatase inhibitor, has more recently
been considered as an additional treatment option for
anovulatory infertility. While longitudinal data does not
yet exist to adequately examine the association between
letrozole use for ovulatory infertility and hormone
related cancer risk, letrozole is currently used as an
adjuvant treatment for hormone receptor positive post-
menopausal breast cancer [115] thus it could be hypoth-
esized that it would likely decrease hormonal related
cancer risk.
Conclusions
The associations between PCOS and endometrial, ovar-
ian, and breast cancer are complex, requiring consider-
ation of PCOS diagnostic criteria, etiologic heterogeneity
of cancer subtypes, confounding and mediating factors,
menopausal status, co-morbid conditions, as well as
treatment options that may also influence cancer risk. In
addition, the rarity of ovarian and endometrial cancers
make these cancers even more difficult to study. Larger
well-designed studies, or pooled analyses, may help clar-
ify these complex associations.
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